Log into PainCareLive on Tuesday, March 13, 2018 at 2:00 PM ET for a live online CME Certified activity discussing the safety, efficacy, and tolerability profiles of abuse-deterrent opioid formulations and their potential to reduce opioid misuse/abuse in treating patients with acute or chronic pain.  This accredited program, Targeting Opioid Misuse: Abuse-Deterrent Formulations in the Management of Acute and Chronic Pain, clinicians will be eligible to earn AMA PRA Category 1 CreditTM and AAFP Prescribed Credit

Dr. Jeffrey Gudin, MD, Director, Pain Management and Palliative Care at Englewood Hospital and Medical Center will lead program with Dr. Charles E. Argoff, MD, Professor of Neurology at Albany Medical College.  Speaking to the PlatformQ Health team, Dr Gudin shared why this online CME program educating clinicians on pain management and abuse deterrent formulations is so important:

“Prescription opioids are powerful pain reducing medications that have both benefits as well as potentially serious risks. As part of a comprehensive plan to address opioid abuse, the FDA has supported the development of a number of abuse deterrent formulations (ADF) of long acting and immediate release (IR) opioids. In light of the current prescribing climate, clinicians need to understand how to assess the benefits and harms of opioid therapies.  This program will introduce and review these abuse deterrent formulations and guide clinicians towards improved prescribing practices.”

Clinicians are continually faced with the dilemma of balancing risks associated with opioids with their patient’s need for adequate pain relief. Recently, we polled clinicians across our network to find out what they believe will have the most positive long-term impact to address the opioid epidemic.  46% of the almost 1,000 clinician respondents selected “increased development of and access to effective, non-addictive pain management therapies”.  Additional responses focused on aligned education and training for opioid prescribers and public addiction education campaigns.

This program will focus on addressing some of these needs by equipping clinicians to:

  • Recognize barriers to treating acute and chronic pain
  • Employ strategies to address the opioid crisis
  • Assess medications to reduce opioid misuse while treating acute and chronic pain
  • Differentiate abuse-deterrent formulations targeting specific routes of misuse/abuse
  • Understand the investigational abuse-deterrent formulations available

Clinicians can submit questions to the panel prior to the program on the PainCareLive QBoard, as well as via the live Q&A feature in the live broadcast.

Register for the upcoming program at PainCareLive.  For more information about this, and other educational programs, contact Lauren Alford at LAlford@platformq.com.